UBS AM
NGNE icon

UBS AM’s Neurogene NGNE Stock Holding History

UBS AM’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.18K Hold
292
– – ﹤0.01% 3300
2026
Q1 		$5.89K Buy
+292
New +$5.66K ﹤0.01% 3429
2021
Q4 		– Sell
-517
Closed -$74.8K – 2885
2021
Q3 		$74.8K Hold
517
– – ﹤0.01% 2732
2021
Q2 		$95.4K Buy
+517
New +$114K ﹤0.01% 2738
2021
Q1 		– Sell
-745
Closed -$210K – 2612
2020
Q4 		$210K Buy
+745
New +$182K ﹤0.01% 2489

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

UBS AM's NGNE Position: Q2 2026 in Review

UBS AM held its Neurogene (NGNE) position steady in Q2 2026 at 292 shares worth $9.18K. The position accounts for ﹤0.01% of the portfolio, ranked #3300.

UBS AM first reported a position in NGNE in Q4 2020 and has held it in 5 quarters since. The position peaked at $210K in Q4 2020. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • UBS AM held 292 shares of Neurogene worth $9.18K as of Q2 2026.
  • UBS AM left its Neurogene share count unchanged in Q2 2026.
  • Neurogene made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3300 holding.
  • UBS AM first reported a position in Neurogene in Q4 2020 and has held it in 5 quarters since.
  • UBS AM's Neurogene position peaked at $210K in Q4 2020.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.